Herpes Zoster During Immunosuppressive Therapy For Autoimmune Diseases by Zahid, Mohammad Faizan et al.
eCommons@AKU
Medical College Documents Medical College, Pakistan
January 2017
Herpes Zoster During Immunosuppressive







Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_mc
Part of the Medical Sciences Commons
Recommended Citation
Zahid, M. F., Ghufran, M., Mansoor, A., Sohail, M. R. (2017). Herpes Zoster During Immunosuppressive Therapy For Autoimmune
Diseases. Journal of Ayub Medical College, 29(3), 481-485.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_mc/62
J Ayub Med Coll Abbottabad 2017;29(3) 
http://www.jamc.ayubmed.edu.pk 481
REVIEW ARTICLE  
HERPES ZOSTER DURING IMMUNOSUPPRESSIVE THERAPY FOR 
AUTOIMMUNE DISEASES 
Mohammad Faizan Zahid, Mariam Ghufran*, Armaghan-e-Rehman Mansoor, 
Muhammad Rizwan Sohail** 
Medical Graduate, Aga Khan University, Karachi-Pakistan, *Aster DM Healthcare, Dubai-UAE, **Division of Infectious Diseases, Mayo 
Clinic College of Medicine, Rochester, MN-USA 
Background: Patients on immunosuppressive therapy are at a greater risk for herpes zoster 
reactivation and are more likely to have adverse outcomes. Propylactic antivrials and vaccinations 
may potentially prevent these complications. Methods: Medical literature addressing the clinical 
course and therapy of herpes zoster in patients receiving immunosuppressive therapy for autoimmune 
disorders, and the roles of anti-viral prophylaxis and vaccination was reviewed. Research databases 
including PubMed, Ovid, Medline, Google Scholar and Cochrane were utilized. Results: Acyclovir 
and its derivatives are most commonly used in this setting for treatment and reduction of post-zoster 
complications. Foscarnet may be used for acyclovir-resistant strains. At both conventional and ultra-
low doses, acyclovir has proven effective when used as prophylaxis, reducing the incidence of zoster 
and its complications in immunosuppressed patients. Additionally, ultra-low doses are associated with 
significantly reduced side effects. The zoster vaccine, Zostavax, a live-attenuated vaccine has shown 
promising results in several clinical trials. However, live-attenuated vaccines should be cautiously used 
in immunosuppressed patients. For patients who require immunosuppressive therapy, vaccination 2–3 
months prior to therapy may be appropriate. Conclusions: Prophylactic antiviral therapy and 
vaccination help significantly reduce morbidity and mortality from zoster reactivation in patients 
receiving immunosuppressive therapy. 
Keywords: Herpes zoster; Auto-immune diseases; Immunosuppressive therapy; Prophylaxis; 
Vaccination 
J Ayub Med Coll Abbottabad 2017;29(3):481–5 
INTRODUCTION 
Varicella-zoster virus (VZV) causes two distinct clinical 
entities in humans. Primary infection due to VZV 
manifests as varicella, commonly known as chickenpox. 
Reactivation of the latent VZV virus after primary 
exposure manifests as a localized, painful eruption of 
vesicles with a distinct dermatomal pattern, known as 
herpes zoster (HZ).1,2 Patients with autoimmune 
disorders treated with immunosuppressive drugs are at a 
higher risk for developing herpes zoster.3,4 In recent 
years, potent immunosuppressive agents are 
increasingly being used in patients with rheumatoid 
arthritis (RA), inflammatory bowel disease (IBD), 
systemic lupus erythematosus (SLE), Wegner’s 
Granulomatosis and other autoimmune diseases.5–7  
After primary infection, VZV lies dormant in 
the dorsal root ganglia and is kept in check by T-cell 
mediated immunity.8 The increase in the risk of VZV 
reactivation in these patients occurs primarily by 
impacting T-cell number and/or T-cell function, all of 
which culminates in the depression of cell-mediated 
immunity.1,9–14 The fall in T-cell mediated immunity 
allows the virus to reactivate and cause HZ.15,16 Patients 
on immunosuppressive therapy for autoimmune 
disorders have a several times greater risk of developing 
VZV reactivation and HZ.17 Immunocompromised 
patients are also at higher risk of developing 
complications associated with VZV reactivation.18,19 Up 
to 40% of immunocompromised patients with HZ 
reactivation have been reported to suffer from severe 
infections with cutaneous and visceral dissemination.19 
Despite aggressive anti-viral therapy, mortality remains 
high at up to 37% in immunocompromised patients.19,20 
This review aims to highlight the treatment of 
overt HZ in patients on immunosuppressive therapy and 
discuss the protective roles of prophylactic antiviral 
drugs and vaccinations to prevent this complication in 
patients receiving immunosuppressive therapy. 
LITERATURE SEARCH 
The PubMed database was searched for articles 
published in the English-language literature. Medical 
subject headings (MeSH) including ‘zoster’, ‘herpes 
zoster’, ‘shingles’, ‘immunosuppression’, 
‘immunosuppressed’, ‘immunocompromised’ were 
cross-referenced in the search, which was supplemented 
with a secondary manual search of PubMed, Ovid 
Medline, Google Scholar and Cochrane databases. 
Further manual searching was carried out by reviewing 
the articles listed in the references of the articles 
obtained from the primary search. 
Clinical presentation and management of herpes 
zoster in immunocompromised patients 
Diminished immunity is a major risk factor for VZV 
reactivation, and several immunosuppressed patients 
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suffer from HZ. The presentation for HZ is 
considerably variable, with some patients presenting 
without dermatological manifestations or with 
atypical features, such as, ataxia and retinitis.21 
Generally, HZ follows a localized and benign course 
in a majority of patients, and complications, 
including but not limited to disseminated disease, 
visceral involvement and post-herpetic neuralgia 
(PHN), tend to be uncommon. However, the 
incidence of disseminated disease is higher in 
immunocompromised patients, with the incidence 
being an estimated 10% for severely 
immunocompromised patients compared to 0.009% 
for all cases.22–24 
The objective of initiating early anti-viral 
therapy is to decrease the risk of visceral and 
cutaneous dissemination as well as to reduce 
morbidity, mortality and complications associated 
with HZ.25 Anti-viral agents, especially acyclovir, its 
derivatives like valacyclovir and famciclovir, and 
systemic vidarabine have been the mainstay of 
therapy for HZ in immunocompromised patients.26 
Early treatment with these agents has been shown to 
be associated with a favourable outcome in several 
studies.22, 25–27  
The optimal time to start anti-viral therapy is 
within 72 hours of onset of rash. Initiating anti-viral 
therapy early is associated with rapid clearance of the 
virus from herpetic lesions, resulting in reduced 
infectivity, accelerated healing of lesions, reduced 
formation of new lesions, reduced risk of PHN and 
decreased risk of cutaneous and visceral 
dissemination.25,28 A randomized trial run by the 
National Institute of Allergy and Infectious Diseases 
Collaborative Anti-viral Study28 showed that patients 
who were subjected to anti-viral pharmacotherapy 
within the first 5 days of onset of HZ did better in 
terms of cessation of viral shedding, crusting and 
healing of old lesions and formation of new lesions, 
than those who received antivirals later than 5 days 
after onset. However, antiviral therapy for 
dermatomal HZ in a patient on immunosuppressant 
therapy should be given even for patients who 
present later, unless lesions are present for more than 
7 days and have already crusted.  
The majority of immunocompromised 
patients with cutaneous HZ do not develop extensive 
and disseminated disease, but it is exceedingly 
difficult to gauge which patients will eventually 
develop disseminated disease. Therefore, early anti-
viral therapy is recommended for all 
immunosuppressed patients who have clinical 
manifestations of dermatomal zoster, as a delay in 
therapy can lead to extensive HZ, an entity with a 
devastating disease course and poor prognosis.19,20 
Oral anti-viral therapy with close outpatient follow 
up is a reasonable approach to mildly 
immunocompromised patients, such as those taking 
non-biologic disease modifying anti-rheumatic drugs 
(DMARDs) or those with localized dermatomal 
HZ.25,26,29 Intensive therapy with hospitalization and 
intravenous anti-viral medications is warranted for 
patients with extensive disease, including those with 
localized ophthalmic involvement or those receiving 
highly immunosuppressive agents such as tumour 
necrosis factor inhibitors.3 
When comparing the outcome of patients 
treated with either acyclovir or vidarabine in 
randomized clinical trials, acyclovir and its 
derivatives have been shown to be superior for the 
treatment of HZ in immunocompromised patients 
than vidarabine.27,30 Patients treated with acyclovir 
showed a shorter duration of time during which viral 
cultures from the lesions were positive, thus 
correlating with a shorter duration of viral shedding 
and infectivity. Acyclovir also showed a remarkable 
decrease in the time needed for lesions to crust and 
eventually heal completely, as well as a shorter 
disease course to pain alleviation and symptomatic 
improvement. Follow-up of the patients participating 
in these trials also showed a significantly low 
incidence of PHN in patients treated with acyclovir 
than those receiving vidarabine. 
In vitro sensitivity of VZV cultures isolated 
from subsequent episodes of HZ from patients who 
had previously suffered from HZ showed no 
remarkable change in isolates in terms of sensitivity 
to acyclovir.31 This indicates that while resistance is 
always a concern with the frequent use of anti-
microbial therapy, resistance of the VZV to acyclovir 
remains rare. Nonetheless, cases of resistant strains of 
VZV, non-responsive to DNA polymerase inhibitors, 
such as acyclovir, have been reported in 
literature.1,25,32 For such cases, foscarnet is an 
effective alternative, but is associated with 
significantly higher renal toxicity.1,25,32,33  
Role of anti-viral prophylaxis 
HZ and its neurological complications such as PHN, 
as well as superimposed bacterial infections have a 
significant impact on the clinical course and outcome 
of patients receiving immunosuppressive therapy. 
Prophylaxis with anti-viral drugs is an attractive 
approach to prevent HZ in patients who are expected 
to receive immunosuppressive medications.12  
Acyclovir is very effective in the treatment 
of primary infections as well as prophylaxis of 
reactivation infections by herpes viruses. It has 
proven to be very efficacious with a limited side 
effect profile, making it a suitable choice for the 
prevention of HZ in immunosuppressed patients.12,29 
Several studies have noted the efficacy of acyclovir 
or valacyclovir prophylactic administration in 
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significantly reducing incidence of HZ in comparison 
to those not receiving prophylaxis.8,34 In addition, 
anti-viral prophylaxis also reduces the duration and 
severity of disease in patients who suffer from HZ 
despite prophylaxis. Prophylaxis has also shown to 
reduce the need for hospitalization due to HZ, and the 
incidence and duration of PHN and other 
complications that may follow as a result of HZ.9 
Another approach that may serve as a potentially 
useful alternative for patients on long-term 
immunosuppressive therapy is ultra-low dose 
therapy. Asano-Mori et al.35 conducted a trial, 
demonstrating the effectiveness of acyclovir 
prophylaxis at doses far lower than the conventional 
dose in patients receiving hematopoietic stem cell 
transplantation (HSCT). At an ultra-low dose of 200 
mg once daily, acyclovir showed remarkable 
capability of preventing HZ, with only 1 out of 137 
patients developing HZ while on prophylaxis. This 
ultra-low dose prophylaxis was continued from after 
post-transplant hospital discharge till the end of 
immunosuppressive therapy and at least one year 
after HSCT. This approach is a potentially useful 
alternative for patients on long-term 
immunosuppressive therapy. The benefits of ultra-
low, dose prophylaxis being its cost-effectiveness, 
ease and convenience of dose administration and 
compliance and far fewer adverse effects in 
comparison to therapeutic doses of acyclovir. The 
same strategy may be applied to patients receiving 
immunosuppressive therapy for autoimmune and 
rheumatologic diseases, though prospective clinical 
studies and trials are needed to objectively validate 
this proposal before its implementation into routine 
clinical practice. 
Regimens intended for prevention of 
infection with other herpes viruses are also protective 
against the reactivation of HZ. For example, 
prophylaxis for genital herpes simplex virus 
(acyclovir; 800 mg twice daily or 400mg thrice daily 
or valacyclovir; 500mg once daily) and 
cytomegalovirus prophylaxis (ganciclovir; 1000mg 
twice daily or 5mg/kg intravenous dose twice 
daily).19,22,34,36  
Role of vaccination 
Zostavax vaccine, developed by Merck & Co., was 
approved for HZ prevention in 2006.37,38 Like the 
varicella vaccine, Zostavax is a live, attenuated viral 
vaccine that contains the vOKA strain of the VZV.39 
The key difference between the varicella vaccine and 
Zostavax is the much higher dose of plaque-forming 
units (PFU) of infectious virions in Zostavax (19,400 
PFU) in comparison to the varicella vaccine (1,350 
PFU).10,37,39 Already approved by the Advisory 
Committee of Immunization Practices, Zostavax is 
licensed to be used in immunocompetent individuals 
above the age of 60 years.40,41 The vaccine effectively 
reduces the incidence and severity of HZ by as much 
as 51%, and in patients who suffered from HZ 
despite immunization, the incidence of neurological 
complications, especially PHN, was also reduced by 
as much as 67%.9,37,42  
However, since it is a is a live viral vaccine, 
Zostavax has the potential to cause disease in patients 
with compromised immune systems and reduced cell 
mediated immunity, depending on the degree of 
immunosuppression.6 This is of concern in patients 
receiving chemotherapy for cancer, and patients with 
rheumatologic and autoimmune diseases receiving 
biologic agents and high dose non-biologic 
DMARDs, where vaccination with live viruses is 
usually contraindicated.6,41 The role of vaccination in 
moderate immunosuppression caused by low doses of 
non-biologic DMARDs, or even low dose biologics, 
is controversial. However, it should be noted that 
some studies have demonstrated benefit of 
vaccination in patients with moderate doses of 
immunosuppressants, hypothesizing that the fall in 
cell mediated immunity is not sufficient to allow the 
virions in the vaccine to cause disease.39,43 Cheetham 
et al.44 recently conducted a large study involving 
14,554 patients receiving immunosuppressive 
therapy. Majority of the patients in this study were 
receiving low dose oral corticosteroids. Out of these 
14,554 patients, 25 (0.51%) out of 4826 patients with 
receiving current immunosuppressant drug therapy 
experienced HZ. None of the patients suffered from 
disseminated VZV infection. 44 These reports 
highlight a potential role of zoster vaccination in a 
subset of patients who receive less intensive 
immunosuppressive therapy, with enough residual 
immune system functionality to mount an adequate 
immune response to derive benefit from 
immunization. 
The effectiveness and tolerance of the 
Zostavax vaccine in patients receiving 
immunosuppressants has been investigated in several 
studies.6,41,42 It has been well tolerated and has proven 
to be sufficiently immunogenic in adult patients with 
various autoimmune disorders including RA, 
psoriasis, psoriatic arthritis, ankylosing spondylitis 
and IBD.10,17,45 For example, in the study by Zhang et 
al.45 immunization with the zoster vaccine was 
associated with a reduced risk of HZ (hazard ratio: 
0.61; 95% CI, 0.52-0.71) at a median follow up of 2 
years. It is notable that despite there being patients 
who were receiving biologic agents for 
immunosuppressive therapy, there was no short term 
increased risk of HZ after vaccination in this study. It 
may be reasonable to consider vaccinating patients 
for HZ who are anticipated to receive 
immunosuppressive therapy, though this approach 
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has not be adequately studies in research studies or 
clinical trials.41 Since the attenuated virions in the 
vaccine continue to replicate in vaccine recipients for 
an uncertain period of time, a reasonably safe time to 
initiate immunosuppressive therapy would be after 
approximately 3 months after vaccination.10,17,45 
Vaccination may also be considered for patients 
receiving immunosuppressive therapy after 
discontinuing their medications, provided an 
appropriate period of time has passed following 
discontinuation.41,46  
CONCLUSION 
In summary, HZ is a frequently observed infectious 
disease in patients receiving immunosuppressive 
therapy. Though it follows a relatively benign course, 
some patients may develop more complicated disease 
resulting in severe morbidity, complications and 
mortality. Therefore, early diagnosis and appropriate 
therapy are critical in this group of patients. 
Acyclovir and its derivatives (valacyclovir and 
famciclovir) show the most promise in terms of 
reducing infectivity, healing of lesions, and reducing 
the incidence and severity of complications 
associated with HZ. Foscarnet, owing to a worse side 
effect profile, is reserved for cases of acyclovir 
resistant disease.  
Anti-viral agents, principally acyclovir, can 
also be used as prophylaxis in patients who are 
scheduled to receive immunosuppressive therapy. 
Several studies have demonstrated this to be an 
attractive choice for such patients. Studies 
investigating the use of ultra-low doses have also 
been used, showing encouraging results with 
significantly reduced side effects, easier dosage 
schedule and higher patient compliance as compared 
to conventional doses of anti-viral agents. 
The zoster vaccine, Zostavax, has been used 
as another method of prophylaxis for such patients, 
showing promising results. While some recommend 
against the use of Zostavax and other live attenuated 
vaccines in immunocompromised patients, it may be 
prudent to vaccinate such patients approximately 3 
months before the start of immunosuppressive 
therapy. 
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